Physician profile
Eric K Chiu
NPI 1538171921
$4,712.82
in general payments reported to CMS, 2019-2025
27 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $340 · 2021: $320 · 2022: $1,250 · 2023: $564 · 2024: $679 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $942.54 | 2022-2025 | Xiidra, Infuse, Miebo |
| Alcon Vision LLC | $480.21 | 2019-2025 | Hydrus Microstent, Tryptyr, Precision 1 |
| Allergan, INC. | $411.13 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $301.76 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $289.35 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $269.43 | 2022-2025 | Tyrvaya |
| Abbvie INC. | $250.46 | 2022-2025 | Lumigan, Alphagan P |
| Harrow Eye, LLC | $173.54 | 2023-2025 | Vevye, Iheezo |
| Johnson & Johnson Surgical Vision, INC. | $164.01 | 2019-2025 | Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $156.36 | 2019-2025 | Cequa, Xelpros |
| Kala Pharmaceuticals, INC. | $147.91 | 2019-2022 | |
| Sight Sciences, INC. | $142.17 | 2024 | Omni Surgical System |
| Glaukos Corporation | $128.71 | 2023 | |
| Thea Pharma INC. | $115.73 | 2022-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $111.83 | 2024-2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $107.32 | 2019-2022 | |
| Horizon Therapeutics Plc | $84.19 | 2019-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $76.46 | 2019-2022 | |
| Biotissue Holdings INC. | $62.33 | 2019-2020 | |
| Astellas Pharma US INC | $58.44 | 2024-2025 | Izervay |
| Shire North American Group INC | $54.37 | 2019 | |
| Ocular Therapeutix, INC. | $40.67 | 2022-2023 | Dextenza |
| Aerie Pharmaceuticals, INC. | $35.73 | 2019-2021 | |
| Rxsight INC | $34.68 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Dompe US, INC. | $33.63 | 2019-2022 | |
| Amgen INC. | $20.46 | 2025 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.